Evidence map›Paper›PMID 41063704›Full record

ArticleHaematologica2026

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study.

Gang An, Jie Jin, Zhen Cai, Hongmei Jing, Chengcheng Fu, Pengcheng He, Zhongjun Xia, Rui Liu, Liang Li, Xue Gai and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Gang AnNational Clinical Research Center for Blood Diseases, State Key Laboratory of Blood Sciences, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin.
Jie JinFirst Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang.
Zhen CaiFirst Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang.
Hongmei JingPeking University Third Hospital, Beijing.
Chengcheng FuFirst Affiliated Hospital, Soochow University, Suzhou.
Pengcheng HeFirst Affiliated Hospital, Xi'an Jiaotong University, Shaanxi.
Zhongjun XiaSun Yat-sen University Cancer Center, Guangzhou.
Rui LiuJohnson and Johnson, Beijing.
Liang LiJohnson and Johnson, Shanghai.
Xue GaiJohnson and Johnson, Beijing.
Hong ZhangJohnson and Johnson, Beijing.
Dian ZhuJohnson and Johnson, Shanghai.
Xinchao LuoJohnson and Johnson, Shanghai.
Binbin SunJohnson and Johnson, Shanghai.
Hongmei XuJohnson and Johnson, Shanghai.
Longen ZhouJohnson and Johnson, Shanghai.
Michela CampagnaJohnson and Johnson, Madrid, Spain.
Tara J MastersonJohnson and Johnson, Spring House, PA.
Bonnie W LauJohnson and Johnson, Spring House, PA.
Thomas RenaudJohnson and Johnson, Raritan, NJ.
Christoph HeuckJohnson and Johnson, Spring House, PA.
Indrajeet SinghJohnson and Johnson, Spring House, PA.
Deeksha VishwamitraJohnson and Johnson, Spring House, PA.
Lugui QiuNational Clinical Research Center for Blood Diseases, State Key Laboratory of Blood Sciences, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin. qiulg@ihcams.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41063704
PMCPMC13040156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.